Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 13,586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed No phase listed Observational

Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer

NCT02050620
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

NCT05712889
View directory record Official record
Conditions
Neoplasms
Interventions
VIP236 (Q3W), VIP236 (Q2W)
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 23, 2026, 4:57 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Roseville, California • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Not applicable Interventional Results available

Implementing BREASTChoice Into Practice

NCT04491591
View directory record Official record
Conditions
Breast Reconstruction, Breast Cancer
Interventions
Breast Reconstruction Education and Support Tool (BREASTChoice), Attention Control Website, Clinician Survey
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 23, 2026, 4:57 PM EDT
Completed No phase listed Observational

Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

NCT00897468
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, medical chart review
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

NCT01585350
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

NCT01959490
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 4:57 PM EDT
Terminated Phase 1 Interventional

Eniluracil Hand Foot Syndrome

NCT00827580
View directory record Official record
Conditions
Breast Cancer, Colon Cancer
Interventions
Eniluracil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 23, 2026, 4:57 PM EDT
Withdrawn Not applicable Interventional

The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers

NCT00815217
View directory record Official record
Conditions
Diabetic Wounds, Venous Stasis Wounds
Interventions
injection of lipoaspirate, control
Procedure · Other
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 4 Interventional Results available

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris

NCT01951417
View directory record Official record
Conditions
Acne
Interventions
Adapalene/BPO Gel, Moisturizer SPF 30, Foam Wash
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Boynton Beach, Florida • Nashville, Tennessee • Carrollton, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 23, 2026, 4:57 PM EDT
Terminated Phase 1Phase 2 Interventional

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

NCT00147550
View directory record Official record
Conditions
Melanoma, Colonic Neoplasms, Breast Neoplasms
Interventions
PD-0325901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Not applicable Interventional

dHACM Mesh In the Treatment of Diabetic Foot Ulcers

NCT02589210
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
EpiFix Mesh
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

NCT00006825
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

NCT03419910
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986165, Cyclosporine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Not applicable Interventional

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

NCT00002310
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Not applicable Interventional

An Intervention to Decrease Fatigue Among Breast Cancer Survivors

NCT00273208
View directory record Official record
Conditions
Fatigue After Adjuvant Breast Cancer Treatment
Interventions
10 week behavioral intervention program
Behavioral
Lead sponsor
Mercy Medical Center
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

NCT03075540
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Genetic Counseling and Testing YouTube Video
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo

NCT01243450
View directory record Official record
Conditions
Acne
Interventions
Tretinoin, placebo
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
958 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mountain Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 23, 2026, 4:57 PM EDT
Terminated Phase 2 Interventional Results available

Panhematin for Prevention of Acute Attacks of Porphyria

NCT02922413
View directory record Official record
Conditions
Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria
Interventions
Hemin for injection, Placebo
Biological · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 23, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 23, 2026, 4:57 PM EDT